Introduction
My last article on Exelixis (EXEL) was nearly a year ago. Back then, I noted the looming competition (immunotherapy) in first-line renal cell carcinoma,
Temporary slowing revenues may precede volatility in shares of Exelixis.
Source: Clover Biotech Research
Immunotherapy was due to take a significant portion of the first-line market, pushing Exelixis' blockbuster drug, cabomeytx, into a smaller market (second-line RCC).
Since the last article, Exelixis has fallen, underperforming the broader market by 27%:
Source: Seeking Alpha
While investors were spooked by slowing cabomeytx sales,
I am confident the future of